Decreased Bone Density (right panel)

 September 12, 2015 – Drug Safety Information: The American Food and Drug Administration (FDA)  has just strengthened the warning for the type 2 diabetes medicines containing  canagliflozin as active ingredient, i.e. Invokana and Invokamet, related to the increased risk of bone …

Type 2 Diabetes: Risk for bone fracture and decreased bone mineral density under canagliflozin therapy Read more »